Wegovy Oral Tablet Approved in the UK: The First GLP-1 Pill for Weight Loss

What Is the Wegovy Oral Tablet?

The Wegovy oral tablet — known clinically as oral semaglutide — is a once-daily pill containing the same active ingredient found in the Wegovy injection. Semaglutide is a GLP-1 receptor agonist, a class of medicines that mimic the gut hormone GLP-1 to suppress appetite, slow gastric emptying, and regulate blood sugar levels.

Until today, semaglutide for weight loss has only been available as a weekly subcutaneous injection. The oral version represents a landmark shift — removing the need for needles entirely and making GLP-1 treatment far more accessible to a wider population.

Is the Wegovy Oral Tablet Now Available in the UK?

Yes. As of 11 June 2026, the MHRA has approved the Wegovy oral tablet for weight management in the UK — making it the first oral GLP-1 medicine licensed for weight loss in the country.

The MHRA's approval of the first oral GLP-1 tablet marks a watershed moment for obesity treatment in the UK — removing the injection barrier that has prevented many patients from accessing this class of medicine.

Key Points on UK Availability

• Regulatory Status: Approved by the MHRA on 11 June 2026 for weight management in adults.
• Private vs NHS Access: Private clinics and pharmacies are expected to offer it first. NHS availability will depend on a subsequent NICE review, typically adding 6–9 months.
• Current Alternatives: The weekly Wegovy injection (semaglutide) and Mounjaro (tirzepatide) remain available and licensed for weight management alongside the new oral option.

How Does the Wegovy Oral Tablet Compare to the Injection?

Both the pill and the injection contain semaglutide, but they work differently in the body. The injection delivers semaglutide directly into subcutaneous tissue, where it is absorbed slowly over the week. The tablet uses a special absorption enhancer (SNAC) to allow semaglutide to pass through the stomach lining — without it, the molecule would be broken down by stomach acid before reaching the bloodstream.

Clinical trials (the OASIS programme) showed the oral semaglutide tablet at 50mg daily produced meaningful weight loss — though slightly less than the 2.4mg weekly injection in head-to-head comparisons. However, for many patients, the convenience of a daily pill over a weekly injection will outweigh a modest difference in efficacy.

How Much Could the Wegovy Oral Tablet Cost in the UK?

Pricing has not yet been confirmed for the UK market. However, based on comparable oral GLP-1 products and the trajectory of injectable GLP-1 medicines in the UK, we can make some informed projections:

• In the US, oral semaglutide for weight loss is priced similarly to the injection — around $1,300–$1,400 per month without insurance.
• In the UK private market, Wegovy injections currently range from approximately £200–£350 per month depending on dose and pharmacy.
• The oral pill may launch at a similar or slightly lower price point — manufacturers have an incentive to price competitively to drive adoption, particularly given the larger addressable market a pill format opens up.

At MedEazy, we will compare oral semaglutide prices across verified UK pharmacies as soon as it becomes available — just as we do for Wegovy, Mounjaro, Saxenda, and Orlistat today.

Who Is the Wegovy Oral Tablet For?

Wegovy oral is indicated for adults with:

• A BMI of 30 or above (obesity), or
• A BMI of 27 or above (overweight) with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol

It is not suitable for everyone. Patients should consult a qualified prescriber before starting any GLP-1 treatment.

What Does This Mean for Weight Loss Affordability in the UK?

The injectable GLP-1 market has been constrained by two factors: needle aversion and supply shortages. A pill format addresses the first directly — and as manufacturing scales, it should help ease the second over time.

Greater accessibility means a larger patient pool, which in turn drives competition between pharmacies and manufacturers. More competition typically means lower prices. If the oral Wegovy tablet launches at a competitive price point and supply is stable, it could meaningfully reduce the cost of GLP-1 treatment in the UK private market over the next 12–24 months.

For the millions of UK adults living with obesity who have avoided injectable treatments due to needle phobia, the pill format could be transformative — not just clinically, but economically.

Summary

• The Wegovy oral tablet (semaglutide) has been approved by the MHRA on 11 June 2026 — the first oral GLP-1 licensed for weight loss in the UK
• NHS access will require a further NICE review — likely 2027 at the earliest
• Pricing is unconfirmed but expected to be broadly in line with the injection
• The pill format could significantly expand access and drive down GLP-1 costs in the UK over time
• MedEazy will compare prices as soon as it launches — see current Wegovy prices here

Sources: MHRA press release, 11 June 2026 | Novo Nordisk | NICE